IRIS Accounts Production v26.1.0.640 03941645 Board of Directors 1.1.25 31.12.25 31.12.25 0 0 false true false false true false Ordinary Share 0.01000 iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 03941645 2024-12-31 03941645 2025-12-31 03941645 2025-01-01 2025-12-31 03941645 2023-12-31 03941645 2024-01-01 2024-12-31 03941645 2024-12-31 03941645 ns15:EnglandWales 2025-01-01 2025-12-31 03941645 ns14:PoundSterling 2025-01-01 2025-12-31 03941645 ns10:Director1 2025-01-01 2025-12-31 03941645 ns10:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 03941645 ns10:SmallEntities 2025-01-01 2025-12-31 03941645 ns10:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 03941645 ns10:SmallCompaniesRegimeForDirectorsReport 2025-01-01 2025-12-31 03941645 ns10:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 03941645 ns10:FullAccounts 2025-01-01 2025-12-31 03941645 ns10:OrdinaryShareClass1 2025-01-01 2025-12-31 03941645 ns10:Director2 2025-01-01 2025-12-31 03941645 ns10:CompanySecretary1 2025-01-01 2025-12-31 03941645 ns10:RegisteredOffice 2025-01-01 2025-12-31 03941645 ns5:CurrentFinancialInstruments 2025-12-31 03941645 ns5:CurrentFinancialInstruments 2024-12-31 03941645 ns5:ShareCapital 2025-12-31 03941645 ns5:ShareCapital 2024-12-31 03941645 ns5:SharePremium 2025-12-31 03941645 ns5:SharePremium 2024-12-31 03941645 ns5:RetainedEarningsAccumulatedLosses 2025-12-31 03941645 ns5:RetainedEarningsAccumulatedLosses 2024-12-31 03941645 ns5:CostValuation 2024-12-31 03941645 ns5:AdditionsToInvestments 2025-12-31 03941645 ns5:CostValuation 2025-12-31 03941645 ns10:OrdinaryShareClass1 2025-12-31 03941645 ns5:RetainedEarningsAccumulatedLosses 2024-12-31 03941645 ns5:SharePremium 2024-12-31 03941645 ns5:RetainedEarningsAccumulatedLosses 2025-01-01 2025-12-31

REGISTERED NUMBER: 03941645 (England and Wales)

Unaudited Financial Statements for the Year Ended 31 December 2025

for

International Bioscience Managers

Limited

International Bioscience Managers

Limited (Registered number: 03941645)

Contents of the Financial Statements

for the Year Ended 31 December 2025

Page |

Company Information | 1 |

Balance Sheet | 2 |

Notes to the Financial Statements | 3 |

International Bioscience Managers

Limited

Company Information

for the Year Ended 31 December 2025

| DIRECTORS: | Jeremy Curnock Cook

| Robert Iggulden

| SECRETARY: | Robert Iggulden

| REGISTERED OFFICE: | 93 Beaumont Road

| London

| W4 5AJ

| REGISTERED NUMBER: | 03941645 (England and Wales)

| ACCOUNTANTS: | Oculus Accountancy Ltd

| 83 Victoria Street

| London

| SW1H 0HW

International Bioscience Managers

Limited (Registered number: 03941645)

Balance Sheet

31 December 2025

| 31.12.25 |  | 31.12.24

| Notes | £ | £ |

FIXED ASSETS

Investments | 4 | 282,161 |  | 161,989 |  |

CURRENT ASSETS

Cash at bank | 37,046 |  | 160,469 |  |

CREDITORS

Amounts falling due within one year | 5 | (32,000 | ) | (32,000 | ) |

NET CURRENT ASSETS | 5,046 |  | 128,469 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 287,207 |  | 290,458 |  |

CAPITAL AND RESERVES

Called up share capital | 6 | 5,721 |  | 5,721 |  |

Share premium | 7 | 1,788,695 |  | 1,788,695 |  |

Retained earnings | 7 | (1,507,209 | ) | (1,503,958 | ) |

SHAREHOLDERS' FUNDS | 287,207 |  | 290,458 |  |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 8 August 2026 and were signed on its behalf by:

Jeremy Curnock Cook - Director

International Bioscience Managers

Limited (Registered number: 03941645)

Notes to the Financial Statements

for the Year Ended 31 December 2025

1. | STATUTORY INFORMATION

| International Bioscience Managers Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| Consolidation

| The company is a parent company subject to the small companies regime. The company and its subsidiary comprise a small group.The company has therefore taken advantage of the option provided by sec 398 of the Companies act 2006 not to prepare group accounts.

| Investments in subsidiaries

| Investment in Subsidiaries are accounted for at cost less any impairment.

| Foreign currencies

| Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

| Turnover

| Turnover comprises revenue recognised by the company in respect of services provided, and received either in cash or equity or debt instruments in other companies, exclusive of Value Added tax.

| Corporate advisory retainers and fund management fees are recognised as services are provided. Success fees are recognised on completion of the event to which they relate.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was NIL (2024 - NIL).

4. | FIXED ASSET INVESTMENTS

| Shares in

| group

| undertakings

£ |

| COST

| At 1 January 2025 | 161,989 |  |

| Additions | 120,172 |  |

| At 31 December 2025 | 282,161 |  |

| NET BOOK VALUE

| At 31 December 2025 | 282,161 |  |

| At 31 December 2024 | 161,989 |  |

International Bioscience Managers

Limited (Registered number: 03941645)

Notes to the Financial Statements - continued

for the Year Ended 31 December 2025

4. | FIXED ASSET INVESTMENTS - continued

| Subsidiary undertakings

| The following were subsidiary undertakings of the company:

| Bioscience Managers Ltd (incorporated in Australia) |  | 50% of ordinary share capital |  |

| The nature of subsidiary undertakings' business was that of fund management.

5. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

| 31.12.25 |  | 31.12.24

£ | £ |

| Other creditors | 32,000 |  | 32,000 |  |

6. | CALLED UP SHARE CAPITAL

| Allotted, issued and fully paid:

| Number: | Class: | Nominal | 31.12.25 |  | 31.12.24

| value: | £ | £ |

| 572,069 | Ordinary Share | .01 | 5,721 |  | 5,721 |  |

7. | RESERVES

| Retained |  | Share |

| earnings |  | premium |  | Totals

£ | £ | £ |

| At 1 January 2025 | (1,503,958 | ) | 1,788,695 |  | 284,737 |  |

| Deficit for the year | (3,251 | ) | (3,251 | ) |

| At 31 December 2025 | (1,507,209 | ) | 1,788,695 |  | 281,486 |  |

8. | RELATED PARTY DISCLOSURES

| International Bioscience Managers Limited director Mr Jeremy Curnock Cook is an executive director of Bioscience Managers Ltd. IBML owns more than 50% of ordinary share capital of the company.